<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156559">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02126592</url>
  </required_header>
  <id_info>
    <org_study_id>12XJ10015</org_study_id>
    <nct_id>NCT02126592</nct_id>
  </id_info>
  <brief_title>The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome</brief_title>
  <official_title>The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <authority>China:Research Committee of Shanghai Renji Hospital</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is an endocrine disease in reproductive women. It is
      characterized by anovulation and hyperandrogenism. Most patients with PCOS have metabolic
      abnormalities such as dyslipidemia, insulin resistance and glucose abnormalities. Almost
      60-80ï¹ªPCOS patients are obesity which exacerbates IR and hyperandrogenism. Obese PCOS
      patients tend to be overeating suggests that impaired appetite regulation might be
      contribute to the pathophysiology of PCOS. Our study is trying to observe difference of
      incretin between PCOS and normal control to figure out whether change of incretin is
      involved in the pathophysiology of PCOS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change in incretin hormones secretion in PCOS patients.</measure>
    <time_frame>up to 14 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>PCOS cohort</arm_group_label>
    <description>Women with PCOS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control cohort</arm_group_label>
    <description>Women without PCOS</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      only plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Polycystic Ovary Syndrome(PCOS)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women at reproductive age

          -  women with PCOS and women without PCOS

        Exclusion Criteria:

          -  young women who had their menarche less than 3 years

          -  women older than 45 years old, Amenorrhea of menopause, hyperglycemia,
             hyperthyroidism, hypothyroidism, heart failure, lung failure, renal failure, anemia,
             dystrophy, gonitis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jing Ma, Dr.</last_name>
    <phone>+86-21-68383083</phone>
    <email>cherry1996@live.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Ma, Dr.</last_name>
      <phone>+86-21-68383083</phone>
      <email>cherry1996@live.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
    <mesh_term>Incretins</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
